147 related articles for article (PubMed ID: 28259294)
1. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
[TBL] [Abstract][Full Text] [Related]
2. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas.
Galeazzi E; Olivero M; Gervasio FC; De Stefani A; Valente G; Comoglio PM; Di Renzo MF; Cortesina G
Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S138-43. PubMed ID: 9065649
[TBL] [Abstract][Full Text] [Related]
3. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
4. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.
Szturz P; Budíková M; Vermorken JB; Horová I; Gál B; Raymond E; de Gramont A; Faivre S
Oral Oncol; 2017 Nov; 74():68-76. PubMed ID: 29103754
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
9. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.
Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F
J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
11. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
12. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.
De Herdt MJ; Baatenburg de Jong RJ
Front Biosci; 2008 Jan; 13():2516-26. PubMed ID: 17981731
[TBL] [Abstract][Full Text] [Related]
13. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
14. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.
Nisa L; Aebersold DM; Giger R; Zimmer Y; Medová M
Pharmacol Ther; 2014 Sep; 143(3):337-49. PubMed ID: 24786972
[TBL] [Abstract][Full Text] [Related]
15. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
17. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
18. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Brauswetter D; Dános K; Gurbi B; Félegyházi ÉF; Birtalan E; Meggyesházi N; Krenács T; Tamás L; Peták I
Virchows Arch; 2016 May; 468(5):579-87. PubMed ID: 26832731
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
20. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
